Get the Stockscreener App
8.92
3.60%
0.31
Pre-market:
8.92
Anavex Life Sciences Corporation stock is traded at $8.92, with a volume of 756.04K.
It is up +3.60% in the last 24 hours and up +7.21% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
See More
Previous Close:
$8.61
Open:
$8.51
24h Volume:
756.04K
Relative Volume:
0.79
Market Cap:
$693.22M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-16.22
EPS:
-0.55
Net Cash Flow:
$-29.31M
1W Performance:
+9.85%
1M Performance:
+7.21%
6M Performance:
-3.15%
1Y Performance:
+139.14%
1-Day Range:
$8.43
$8.945
1-Week Range:
$7.97
$8.945
52-Week Range:
$3.6337
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
8.92 | 693.22M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences ... - Bluefield Daily Telegraph
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm - GlobeNewswire Inc.
Wealth Enhancement Advisory Services LLC Boosts Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. Appoints Ulrich Elben, as Vice President of Preclinical Operations - marketscreener.com
Anavex Life Sciences Approves Key Amendments at Annual Meeting - TipRanks
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn - Yahoo Finance
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016AVXL - ACCESS Newswire
Cetera Investment Advisers Acquires New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Bank of America Corp DE Sells 76,485 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Ameriprise Financial Inc. Buys 3,243 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Millennium Management LLC Sells 133,208 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Holdings Lessened by BNP Paribas Financial Markets - Defense World
Deutsche Bank AG Has $693,000 Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
D. E. Shaw & Co. Inc. Purchases Shares of 105,130 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Northern Trust Corp Raises Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
The Manufacturers Life Insurance Company Has $298,000 Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
HC Wainwright Issues Positive Forecast for AVXL Earnings - Defense World
Anavex Life Sciences Corp.'s (NASDAQ:AVXL) largest shareholders are individual investors with 60% ownership, institutions own 37% - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Tower Research Capital LLC TRC Buys 1,708 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Does Anavex's Alzheimer's Drug Actually Confer Benefit Over Three Years? (NASDAQ:AVXL) - Seeking Alpha
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlight - GuruFocus
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Call Transcript - Insider Monkey
Anavex Life Sciences to Participate at Upcoming Healthcare Confe - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences | AVXL Stock News - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences - The Manila Times
Anavex Brings Alzheimer's and Parkinson's Drug Updates to Prestigious Wainwright Healthcare Conferences - Stock Titan
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot - CT Insider
Anavex Life Sciences Reports Q2 2025 Financial Results - TipRanks
Raymond James Financial Inc. Makes New $167,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Earnings call transcript: Anavex Life Sciences Q2 2025 reports net loss, stock rises - Investing.com Nigeria
Anavex Life Sciences (AVXL) Q2 Earnings Exceed Expectations - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financia - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update - The Manila Times
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update | AVXL Stock News - GuruFocus
Anavex Life Sciences Corp. Reports Q2 Fiscal 2025 Financial Results and Updates on Clinical Developments - Nasdaq
Anavex Life Sciences Corp. Q2 Loss Beats Estimates - Nasdaq
Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times
Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq
Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):